Alligator Bioscience
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
ATORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000767188 (+8 more)
- LEI:
- 549300E15VI0MB7LXV19
- Country:
- Sweden
- Address:
- C/O Medicon Village, 223 81 Lund
- Sector:
- Manufacturing
Description
Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-10-24 08:00 | English | 3.2 MB | |||
| 2019-08-20 16:35 |
Alligator Bioscience signs antibody agreement for Greater China with Biotheus I…
|
English | 116.0 KB | ||
| 2019-08-20 16:35 |
Alligator Bioscience tecknar antikroppsavtal med Biotheus Inc. i Kina
|
Swedish | 80.7 KB | ||
| 2019-07-31 07:30 |
Alligator Bioscience återtar de globala rättigheterna för CD40-antikroppen ADC-…
|
Swedish | 85.0 KB | ||
| 2019-07-31 07:30 |
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antib…
|
English | 128.2 KB | ||
| 2019-07-11 08:00 | Swedish | 3.0 MB | |||
| 2019-07-11 08:00 | English | 2.9 MB | |||
| 2019-06-18 16:15 |
Alligator Bioscience submits clinical trial application for ATOR-1017
|
English | 97.0 KB | ||
| 2019-06-18 16:15 |
Alligator Bioscience ansöker om att starta klinisk prövning för ATOR-1017
|
Swedish | 78.3 KB | ||
| 2019-05-16 08:30 |
Alligator Bioscience presenterar klinisk studiedesign för ATOR-1015 på ASCO
|
Swedish | 113.2 KB | ||
| 2019-05-16 08:30 |
Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO
|
English | 105.8 KB | ||
| 2019-05-15 23:00 |
Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO
|
English | 108.2 KB | ||
| 2019-05-15 23:00 |
Alligator Bioscience: Klinisk fas I-data för ADC-1013 presenteras på ASCO
|
Swedish | 83.7 KB | ||
| 2019-05-09 17:45 |
Kommuniké från årsstämma den 9 maj 2019 i Alligator Bioscience AB (publ)
|
Swedish | 80.0 KB | ||
| 2019-05-09 17:45 |
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ…
|
English | 107.5 KB |
Automate Your Workflow. Get a real-time feed of all Alligator Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alligator Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alligator Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-28 | Peter Ostler | Other | Sell | 1,658,134 | 179,045.31 SEK |
| 2024-04-11 | Staffan Encrantz | Other | Sell | 44,108,581 | 47,196,181.67 SEK |
| 2022-10-27 | Sören Bregenholt Frederiksen | Other | Buy | 52,000 | 72,748.00 SEK |
| 2022-10-25 | Marie Svensson | Other | Buy | 12,000 | 16,632.00 SEK |
| 2022-08-19 | Sören Bregenholt Frederiksen | Other | Buy | 13,906 | 25,726.10 SEK |
| 2022-08-18 | Sören Bregenholt Frederiksen | Other | Buy | 31,094 | 56,911.35 SEK |
| 2022-05-31 | Peter Ostler | Other | Buy | 100,000 | 151,500.00 SEK |
| 2022-05-04 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,895.00 SEK |
| 2022-05-02 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 50,811.00 SEK |
| 2022-04-30 | Sören Bregenholt Frederiksen | Other | Buy | 30,000 | 51,171.00 SEK |
Peer Companies
